Brimonidine is an α2 agonist medication used to treat open-angle glaucoma, ocular hypertension, and rosacea.[5][6] In rosacea it improves the redness.[6] It is used as eye drops or applied to the skin.[5][6] It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate.[7]
Common side effects when used in the eyes include itchiness, redness, and a dry mouth.[5]
Brimonidine was patented in 1972 and came into medical use in 1996.[8] It is available as a generic medication.[9][10] In 2023, it was the 213th most commonly prescribed medication in the United States, with more than 2million prescriptions.[11][12]
Brimonidine is indicated for the lowering of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2] It is also used to reduce redness of the eye.[4] The gel is indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.[3]
A 2017 Cochrane review found insufficient evidence to determine if brimonidine slows optic nerve damage.[13]
Brimonidine is an α2 adrenergic agonist.[5]
Peripheral α2 agonist activity results in vasoconstriction of blood vessels (as opposed to central α2 agonist activity that decreases sympathetic tone, as can be seen by the medication clonidine). This vasoconstriction may explain the acute reduction in aqueous humor flow. The increased uveoscleral outflow from prolonged use may be explained by increased prostaglandin release due to α adrenergic stimulation. This may lead to relaxed ciliary muscle and increased uveoscleral outflow.[14]
It is sold under the brand names Alphagan, Alphagan-P, Mirvaso, Lumify, Brymont, and others.
